Cancer Research SABCS  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 67, 318, January 1, 2007. doi: 10.1158/0008-5472.CAN-06-2164
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Farhana, L.
Right arrow Articles by Fontana, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Farhana, L.
Right arrow Articles by Fontana, J. A.

Experimental Therapeutics, Molecular Targets, and Chemical Biology

Adamantyl-Substituted Retinoid-Related Molecules Bind Small Heterodimer Partner and Modulate the Sin3A Repressor

Lulu Farhana1, Marcia I. Dawson2, Mark Leid3, Li Wang4, David D. Moore5, Gang Liu2, Zeben Xia2 and Joseph A. Fontana1

1 John D. Dingell Veterans Affairs Medical Center and Department of Medicine, Wayne State University and Karmanos Cancer Institute, Detroit, Michigan; 2 Burnham Institute, La Jolla, California; 3 Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, Oregon; 4 Department of Medicine and Pharmacology, The University of Kansas Medical Center, Kansas City, Kansas; and 5 Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas

Requests for reprints: Joseph A. Fontana, John D. Dingell Veterans Affairs Medical Center, Oncology 11M-HO, 4646 John R. Street, Detroit, MI 48201. Phone: 313-576-3659; Fax: 313-576-1122; E-mail: Joseph.Fontana{at}va.gov.

6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid (CD437/AHPN) and 4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC/MM002) are inducers of apoptosis of malignant cells both in vitro and in vivo. Numerous mechanisms have been proposed for how these compounds exert this effect. This report shows that AHPN/3-Cl-AHPC binds specifically to the orphan nuclear receptor small heterodimer partner (SHP; NR0B2), and this binding promotes interaction of the receptor with a corepressor complex that minimally contains Sin3A, N-CoR, histone deacetylase 4, and HSP90. Formation of the SHP-Sin3A complex is essential for the ability of AHPN and 3-Cl-AHPC to induce apoptosis, as both knockout SHP and knockdown of Sin3A compromise the proapoptotic activity of these compounds but not other apoptosis inducers. These results suggest that AHPN/3-Cl-AHPC and their analogues are SHP ligands and their induction of apoptosis is mediated by their binding to the SHP receptor. [Cancer Res 2007;67(1):318–25]




This article has been cited by other articles:


Home page
Mol. Cell. Biol.Home page
J. Miao, S. Fang, J. Lee, C. Comstock, K. E. Knudsen, and J. K. Kemper
Functional Specificities of Brm and Brg-1 Swi/Snf ATPases in the Feedback Regulation of Hepatic Bile Acid Biosynthesis
Mol. Cell. Biol., December 1, 2009; 29(23): 6170 - 6181.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
L. Farhana, M. I. Dawson, L. Xu, J.-H. Dannenberg, and J. A. Fontana
SHP and Sin3A expression are essential for adamantyl-substituted retinoid-related molecule-mediated nuclear factor-{kappa}B activation, c-Fos/c-Jun expression, and cellular apoptosis
Mol. Cancer Ther., June 1, 2009; 8(6): 1625 - 1635.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
R. R.M. Maran, A. Thomas, M. Roth, Z. Sheng, N. Esterly, D. Pinson, X. Gao, Y. Zhang, V. Ganapathy, F. J. Gonzalez, et al.
Farnesoid X Receptor Deficiency in Mice Leads to Increased Intestinal Epithelial Cell Proliferation and Tumor Development
J. Pharmacol. Exp. Ther., February 1, 2009; 328(2): 469 - 477.
[Abstract] [Full Text] [PDF]


Home page
PhysiologyHome page
J. J. Eloranta and G. A. Kullak-Ublick
The Role of FXR in Disorders of Bile Acid Homeostasis
Physiology, October 1, 2008; 23(5): 286 - 295.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
C. Valli, G. Paroni, A. M. Di Francesco, R. Riccardi, M. Tavecchio, E. Erba, A. Boldetti, M. Gianni', M. Fratelli, C. Pisano, et al.
Atypical retinoids ST1926 and CD437 are S-phase-specific agents causing DNA double-strand breaks: significance for the cytotoxic and antiproliferative activity
Mol. Cancer Ther., September 1, 2008; 7(9): 2941 - 2954.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. Sanyal, A. Bavner, A. Haroniti, L.-M. Nilsson, T. Lundasen, S. Rehnmark, M. R. Witt, C. Einarsson, I. Talianidis, J.-a. Gustafsson, et al.
Involvement of corepressor complex subunit GPS2 in transcriptional pathways governing human bile acid biosynthesis
PNAS, October 2, 2007; 104(40): 15665 - 15670.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.